Last reviewed · How we verify
BAY3018250 Dose 1
BAY3018250 is a small molecule drug that targets the molecular target.
BAY3018250 is a small molecule drug that targets the molecular target. Used for Phase 2 clinical trials for BAY3018250 are ongoing, but the specific indication is not publicly disclosed..
At a glance
| Generic name | BAY3018250 Dose 1 |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of BAY3018250 is not well understood, but it is believed to work by interacting with the molecular target, leading to a specific therapeutic effect.
Approved indications
- Phase 2 clinical trials for BAY3018250 are ongoing, but the specific indication is not publicly disclosed.
Common side effects
- Unknown
Key clinical trials
- A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis (PHASE2)
- A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants (PHASE1)
- A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAY3018250 Dose 1 CI brief — competitive landscape report
- BAY3018250 Dose 1 updates RSS · CI watch RSS
- Bayer portfolio CI